TGX-115

• Description :

  TGX-115 is a p110β/p110δ-selective, PI3-K inhibitor. TGX-115 blocks p110β-mediated Akt phosphorylation induced by lysophosphatidic acid (LPA) in L6 myotubes, reduces insulin-stimulated PI (3,4) P2 and PIP3 levels in 3T3-L1 adipocytes. TGX-115 can be used for the study of diabetes mellitus[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319

• Target :

  PI3K

• Type :

  Reference compound

• Related Pathways :

  PI3K/Akt/mTOR

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/tgx-115.html

• Purity :

  99.25

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C1C=C(N2CCOCC2)NC3=C1C=CC=C3OC4=C(C)C=CC=C4

• Molecular Formula :

  C20H20N2O3

• Molecular Weight :

  336.38

• Precautions :

  H315, H319

• References & Citations :

  [1]Fan QW, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. 2006 May;9 (5) :341-9. |[2]Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125 (4) :733-47.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PI3Kβ; PI3Kδ

• CAS Number :

  [351071-62-0]